权重远期预后的结果是儿童系统性红斑狼疮治疗的根据

Weight evaluation of long-term prognosis： criterion of the treatment on childhood-onset systemic lupus erythe- matosus

现沦述的主要为系统性红斑狼疮（SLE）积极的治疗理念和远期愈后的证据强度间的关系，即儿童SLE的整体愈后得益于狼疮性肾炎（LN）生存状况的改善。后设分析总体结论的差异还有待进一步论证。将儿童SLE远期预后与成年患者的差异、儿童疾病异质性的规律、准确反映疾病状态的生物学标记、药物遗传学／药物基因组学的影响作为加强早期诱导治疗的证据，优化已有的免疫调节／抑制剂方案，早期治疗确立在临床症状期前的愿望才能实现。

This article mainly discusses the relationship between the active treatment concept of the systemic lupus erythematosus（SLE） and its positive outcome in long-term prognosis,which is the overall prognosis of SLE bene- fits from the improvement on the living conditions of patients with lupus nephritis （LN）. Although more argumentations are still required in regards to whether to use the different general conclusions of the meta analysis between the child- hood-onset SLE （cSLE） and the early adulthood-onset SLE patients at the same age as more proactive induction therapy in early phase, yet the time point for early therapy before clinical symptoms appearing can be determined and thereby positive anticipation can be achieved through keeping the difference between the long-term prognosis of the cSLE and the adult-onset patients as evidences, and making in-depth study on the innate laws of the heterogeneity of cSLE,mean- while giving biological markers more application which can be highly reliable in reflecting the morbid status, supported by the study outcomes of pharmacogenetics/pharmacogenomics and further optimization of current immunoregulation/ immune inhibitors approaches （as evidences required by long-term effects）.